Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Oncol Rep

Retrieve available abstracts of 70 articles:
HTML format

Single Articles

    July 2021
  1. YAO J, Luo Y, Zeng C, He H, et al
    UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

  2. SHI YF, Huang ZY, Huang YS, Dong RJ, et al
    Interaction between CD9 and PI3Kp85 activates the PI3K/AKT signaling pathway in Blineage acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

  3. LIU YH, Zhu M, Lei PP, Pan XY, et al
    ND09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCRABL signaling.
    Oncol Rep. 2021;46.
    PubMed     Abstract available

    June 2021
  4. DONG L, Xu WW, Li H, Bi KH, et al
    [Retracted] In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrialmediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration.
    Oncol Rep. 2021;45.
    PubMed     Abstract available

    April 2021
  5. JIANG H, Tang J, Qiu L, Zhang Z, et al
    Semaphorin 4D is a potential biomarker in pediatric leukemia and promotes leukemogenesis by activating PI3K/AKT and ERK signaling pathways.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available

  6. ZHOU H, Ning Y, Zeng G, Zhou C, et al
    Curcumin promotes cell cycle arrest and apoptosis of acute myeloid leukemia cells by inactivating AKT.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available

    March 2021
  7. JING W, Zhou M, Chen R, Ye X, et al
    In vitro and ex vivo antitumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2overexpressing leukemia cells.
    Oncol Rep. 2021;45:1142-1152.
    PubMed     Abstract available

    November 2020
  8. MEI S, Zhang Y, Yu L, Chen G, et al
    Expression and role of fibroblast activation protein alpha in acute myeloid leukemia.
    Oncol Rep. 2020 Nov 30. doi: 10.3892/or.2020.7874.
    PubMed     Abstract available

  9. ZHANG H, Wang Y, Yang H, Huang Z, et al
    TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/betacatenin/TCF7/ABC transporter signaling axis.
    Oncol Rep. 2020 Nov 27. doi: 10.3892/or.2020.7869.
    PubMed     Abstract available

  10. TAKEDA T, Tsubaki M, Genno S, Nemoto C, et al
    AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitorsensitive and resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
    Oncol Rep. 2020;44:2211-2218.
    PubMed     Abstract available

    September 2020
  11. XU W, Huang Z, Gan Y, Chen R, et al
    Casein kinase 1alpha inhibits p53 downstream of MDM2mediated autophagy and apoptosis in acute myeloid leukemia.
    Oncol Rep. 2020 Sep 9. doi: 10.3892/or.2020.7760.
    PubMed     Abstract available

  12. FAN Z, Luo H, Zhou J, Wang F, et al
    Checkpoint kinase1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
    Oncol Rep. 2020 Sep 7. doi: 10.3892/or.2020.7757.
    PubMed     Abstract available

    August 2020
  13. WANG T, Du J, Kong D, Yang G, et al
    Gambogic acid inhibits proliferation and induces apoptosis of human acute Tcell leukemia cells by inducing autophagy and downregulating betacatenin signaling pathway: Mechanisms underlying the effect of Gambogic acid on TALL cells.
    Oncol Rep. 2020 Aug 11. doi: 10.3892/or.2020.7726.
    PubMed     Abstract available

  14. NAPOLITANO R, De Matteis S, Carloni S, Bruno S, et al
    Kevetrin induces apoptosis in TP53 wildtype and mutant acute myeloid leukemia cells.
    Oncol Rep. 2020 Aug 11. doi: 10.3892/or.2020.7730.
    PubMed     Abstract available

  15. XU Y, Lin Y, Luo Y, Yang Y, et al
    RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2deficient human acute myeloid leukemia.
    Oncol Rep. 2020 Aug 10. doi: 10.3892/or.2020.7723.
    PubMed     Abstract available

  16. DONG A, Yang W, Huang H, Zhou X, et al
    Bioinformatics analysis of the network of histone H3 lysine 9 trimethylation in acute myeloid leukaemia.
    Oncol Rep. 2020;44:543-554.
    PubMed     Abstract available

    July 2020
  17. JIN J, Li X, Guo W, Li F, et al
    Novel SAHAbendamustine hybrid NL101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
    Oncol Rep. 2020;44:273-282.
    PubMed     Abstract available

  18. PUENTE-MONCADA N, Turos-Cabal M, Sanchez-Sanchez AM, Antolin I, et al
    Role of glucose metabolism in the differential antileukemic effect of melatonin on wildtype and FLT3ITD mutant cells.
    Oncol Rep. 2020;44:293-302.
    PubMed     Abstract available

    February 2020
  19. XIONG Q, Huang S, Li YH, Lv N, et al
    Singlecell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction.
    Oncol Rep. 2020 Feb 18. doi: 10.3892/or.2020.7507.
    PubMed     Abstract available

    January 2020
  20. MA P, Xing M, Han L, Gan S, et al
    High PDL1 expression drives glycolysis via an Akt/mTOR/HIF1alpha axis in acute myeloid leukemia.
    Oncol Rep. 2020 Jan 23. doi: 10.3892/or.2020.7477.
    PubMed     Abstract available

  21. LI S, Bo Z, Jiang Y, Song X, et al
    Homoharringtonine promotes BCRABL degradation through the p62mediated autophagy pathway.
    Oncol Rep. 2020;43:113-120.
    PubMed     Abstract available

    December 2019
  22. TENG Z, Xu S, Lei Q
    Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Oncol Rep. 2019 Dec 31. doi: 10.3892/or.2019.7453.
    PubMed     Abstract available

    November 2019
  23. MA W, Liu F, Yuan L, Zhao C, et al
    Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt/betacatenin pathway.
    Oncol Rep. 2019 Nov 19. doi: 10.3892/or.2019.7408.
    PubMed     Abstract available

  24. PANDEY S, Moazam M, Ghimirey N, Kuerbitz SJ, et al
    WT1 regulates cyclin A1 expression in K562 cells.
    Oncol Rep. 2019;42:2016-2028.
    PubMed     Abstract available

    October 2019
  25. YU G, Yin C, Wu F, Jiang L, et al
    Gene mutation profile and risk stratification in AML1ETOpositive acute myeloid leukemia based on nextgeneration sequencing.
    Oncol Rep. 2019 Oct 15. doi: 10.3892/or.2019.7375.
    PubMed     Abstract available

    September 2019
  26. ISHIKAWA M, Iriyama N, Tokuhira M, Takaku T, et al
    Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
    Oncol Rep. 2019 Sep 27. doi: 10.3892/or.2019.7339.
    PubMed     Abstract available

  27. RYU MJ, Han J, Kim SJ, Lee MJ, et al
    PTEN/AKT signaling mediates chemoresistance in refractory acute myeloid leukemia through enhanced glycolysis.
    Oncol Rep. 2019 Sep 12. doi: 10.3892/or.2019.7308.
    PubMed     Abstract available

  28. LI H, Li J, Cheng J, Chen X, et al
    AMLderived mesenchymal stem cells upregulate CTGF expression through the BMP pathway and induce K562ADM fusiform transformation and chemoresistance.
    Oncol Rep. 2019;42:1035-1046.
    PubMed     Abstract available

    June 2019
  29. LIU C, Li Y, Hu R, Han W, et al
    Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinibbased therapy.
    Oncol Rep. 2019 Jun 11. doi: 10.3892/or.2019.7194.
    PubMed     Abstract available

  30. SAKURAI N, Komada Y, Hanaki R, Morimoto M, et al
    Role of microRNAs in glucocorticoidresistant Bcell precursor acute lymphoblastic leukemia.
    Oncol Rep. 2019 Jun 10. doi: 10.3892/or.2019.7191.
    PubMed     Abstract available

  31. YU X, Zhang H, Yuan M, Zhang P, et al
    Identification and characterization of a murine model of BCRABL1+ acute Blymphoblastic leukemia with central nervous system metastasis.
    Oncol Rep. 2019 Jun 3. doi: 10.3892/or.2019.7184.
    PubMed     Abstract available

  32. ZHANG R, Deng Q, Jiang YY, Zhu HB, et al
    Effect and changes in PD1 expression of CD19 CART cells from T cells highly expressing PD1 combined with reduceddose PD1 inhibitor.
    Oncol Rep. 2019;41:3455-3463.
    PubMed     Abstract available

    May 2019
  33. BRIGHT SA, Byrne AJ, Vandenberghe E, Browne PV, et al
    Selected nitrostyrene compounds demonstrate potent activity in chronic lymphocytic leukaemia cells, including those with poor prognostic markers.
    Oncol Rep. 2019;41:3127-3136.
    PubMed     Abstract available

    April 2019
  34. BAI J, Li L, Li Y, Chen Q, et al
    Methylation of the promoter region of the MTRR gene in childhood acute lymphoblastic leukemia.
    Oncol Rep. 2019 Apr 12. doi: 10.3892/or.2019.7114.
    PubMed     Abstract available

  35. IBRAHIM SM, Bakhashab S, Ilyas AM, Pushparaj PN, et al
    WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines.
    Oncol Rep. 2019 Apr 2. doi: 10.3892/or.2019.7093.
    PubMed     Abstract available

  36. YANG Y, Dai W, Sun Y, Zhao Z, et al
    Long noncoding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells.
    Oncol Rep. 2019;41:2311-2320.
    PubMed     Abstract available

    March 2019
  37. HUANG R, Liao X, Li J, Wei J, et al
    Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
    Oncol Rep. 2019 Mar 18. doi: 10.3892/or.2019.7075.
    PubMed     Abstract available

  38. WANG H, Dong R, Fan WW, Zheng XC, et al
    Timosaponin AIII induces autophagy of Tcell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway.
    Oncol Rep. 2019 Mar 15. doi: 10.3892/or.2019.7072.
    PubMed     Abstract available

  39. LI Y, Zhao L, Li N, Miao Y, et al
    [Corrigendum] miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
    Oncol Rep. 2019 Mar 13. doi: 10.3892/or.2019.7057.
    PubMed     Abstract available

  40. LEE HR, Baek KH
    Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
    Oncol Rep. 2019 Mar 13. doi: 10.3892/or.2019.7059.
    PubMed     Abstract available

  41. BASHANFER SAA, Saleem M, Heidenreich O, Moses EJ, et al
    Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells.
    Oncol Rep. 2019;41:2027-2040.
    PubMed     Abstract available

    January 2019
  42. PILLOZZI S, Bernini A, Spiga O, Lelli B, et al
    Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrowinduced chemoresistance in acute leukemias.
    Oncol Rep. 2019;41:312-324.
    PubMed     Abstract available

    December 2018
  43. JIANG M, Zou X, Lu L
    Potential efficacy and prognosis of silencing the CRLF2mediated AKT/mTOR pathway in pediatric acute Bcell lymphoblastic leukemia.
    Oncol Rep. 2018 Dec 7. doi: 10.3892/or.2018.6917.
    PubMed     Abstract available

  44. FU J, Si L, Zhuang Y, Zhang A, et al
    Wnt/betacatenin inhibition reverses multidrug resistance in pediatric acute lymphoblastic leukemia.
    Oncol Rep. 2018 Dec 4. doi: 10.3892/or.2018.6902.
    PubMed     Abstract available

    November 2018
  45. JING W, Li J
    Identification of biomarkers for the prediction of relapsefree survival in pediatric Bprecursor acute lymphoblastic leukemia.
    Oncol Rep. 2018 Nov 2. doi: 10.3892/or.2018.6846.
    PubMed     Abstract available

  46. ZHANG C, Guo LY, Mu D, Gong JH, et al
    Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin.
    Oncol Rep. 2018 Nov 2. doi: 10.3892/or.2018.6849.
    PubMed     Abstract available

    October 2018
  47. RYU I, Ryu MJ, Han J, Kim SJ, et al
    LDeprenyl exerts cytotoxicity towards acute myeloid leukemia through inhibition of mitochondrial respiration.
    Oncol Rep. 2018 Oct 1. doi: 10.3892/or.2018.6753.
    PubMed     Abstract available

    September 2018
  48. ZHAO W, Wang L, Yu Y
    Gene module analysis of juvenile myelomonocytic leukemia and screening of anticancer drugs.
    Oncol Rep. 2018 Sep 18. doi: 10.3892/or.2018.6709.
    PubMed     Abstract available

  49. PANG X, Wang Y, Zhang S, Tan Z, et al
    Altered susceptibility to apoptosis and Nglycan profiles of hematopoietic KG1a cells following coculture with bone marrowderived stromal cells under hypoxic conditions.
    Oncol Rep. 2018;40:1477-1486.
    PubMed     Abstract available

    August 2018
  50. ZHAO Y, Zhong L, Liu L, Yao SF, et al
    Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells.
    Oncol Rep. 2018;40:877-886.
    PubMed     Abstract available

    June 2018
  51. YU J, Guo XL, Bai YY, Yang JJ, et al
    Genomewide profiling of lncRNA expression patterns in patients with acute promyelocytic leukemia with differentiation therapy.
    Oncol Rep. 2018 Jun 25. doi: 10.3892/or.2018.6521.
    PubMed     Abstract available

  52. ZHANG XH, Yang L, Liu XJ, Zhan Y, et al
    Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia.
    Oncol Rep. 2018 Jun 19. doi: 10.3892/or.2018.6508.
    PubMed     Abstract available

    May 2018
  53. ZOVKO A, Yektaei-Karin E, Salamon D, Nilsson A, et al
    Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
    Oncol Rep. 2018 May 25. doi: 10.3892/or.2018.6465.
    PubMed     Abstract available

    April 2018
  54. CHEN N, Feng L, Qu H, Lu K, et al
    Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia.
    Oncol Rep. 2018 Apr 12. doi: 10.3892/or.2018.6367.
    PubMed     Abstract available

    February 2018
  55. MA X, Zhou X, Qu H, Ma Y, et al
    TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
    Oncol Rep. 2018 Feb 7. doi: 10.3892/or.2018.6249.
    PubMed     Abstract available

  56. DONG L, Xu WW, Li H, Bi KH, et al
    In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrial-mediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration.
    Oncol Rep. 2018;39:597-602.
    PubMed     Abstract available

    January 2018
  57. LI GY, Liu JZ, Zhang L, Liu GZ, et al
    Knockdown of immature colon carcinoma transcript 1 induces suppression of proliferation, S-phase arrest and apoptosis in leukemia cells.
    Oncol Rep. 2018 Jan 3. doi: 10.3892/or.2018.6185.
    PubMed     Abstract available

  58. LEE KW, Um ES, Jung BB, Choi ES, et al
    Rhus verniciflua Stokes extract induces inhibition of cell growth and apoptosis in human chronic myelogenous leukemia K562 cells.
    Oncol Rep. 2018 Jan 3. doi: 10.3892/or.2018.6179.
    PubMed     Abstract available

  59. HUANG R, Liu H, Chen Y, He Y, et al
    EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Oncol Rep. 2018;39:119-128.
    PubMed     Abstract available

    December 2017
  60. LIN MW, Yang JS, Lu CC, Lin C, et al
    2-Phenyl-4-quinolone (YT-1) induces G2/M phase arrest and an intrinsic apoptotic mechanism in human leukemia cells.
    Oncol Rep. 2017 Dec 20. doi: 10.3892/or.2017.6170.
    PubMed     Abstract available

    November 2017
  61. YANG JS, Lee CY, Cho HC, Lu CC, et al
    ITR284 modulates cell differentiation in human chronic myelogenous leukemia K562 cells.
    Oncol Rep. 2017 Nov 9. doi: 10.3892/or.2017.6090.
    PubMed     Abstract available

    September 2017
  62. SHEN Y, Liu Q, Lou S, Luo Y, et al
    Decreased expression of the augmenter of liver regeneration results in growth inhibition and increased chemosensitivity of acute T lymphoblastic leukemia cells.
    Oncol Rep. 2017 Sep 21. doi: 10.3892/or.2017.5984.
    PubMed     Abstract available

    July 2017
  63. HUANG JL, Liu W, Tian LH, Chai TT, et al
    Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia.
    Oncol Rep. 2017 Jul 10. doi: 10.3892/or.2017.5802.
    PubMed     Abstract available

    June 2017
  64. HAN XJ, Shi SL, Wei YF, Jiang LP, et al
    Involvement of mitochondrial dynamics in the antineoplastic activity of cisplatin in murine leukemia L1210 cells.
    Oncol Rep. 2017 Jun 28. doi: 10.3892/or.2017.5765.
    PubMed     Abstract available

  65. JI Y, Ma Y, Chen X, Ji X, et al
    Microvesicles released from human embryonic stem cell derived-mesenchymal stem cells inhibit proliferation of leukemia cells.
    Oncol Rep. 2017 Jun 16. doi: 10.3892/or.2017.5729.
    PubMed     Abstract available

  66. LIU Y, Shin DY, Oh S, Kim S, et al
    KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells.
    Oncol Rep. 2017 Jun 1. doi: 10.3892/or.2017.5688.
    PubMed     Abstract available

  67. KONG X, Luo J, Xu T, Zhou Y, et al
    Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP.
    Oncol Rep. 2017;37:3423-3432.
    PubMed     Abstract available

  68. KIM DM, Jang H, Shin MG, Kim JH, et al
    beta-catenin induces expression of prohibitin gene in acute leukemic cells.
    Oncol Rep. 2017;37:3201-3208.
    PubMed     Abstract available

    May 2017
  69. ZHOU HR, Fu HY, Wu DS, Zhang YY, et al
    Relationship between epigenetic changes in Wnt antagonists and acute leukemia.
    Oncol Rep. 2017;37:2663-2671.
    PubMed     Abstract available

    March 2017
  70. CHEN JR, Jia XH, Wang H, Yi YJ, et al
    With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells.
    Oncol Rep. 2017 Mar 29. doi: 10.3892/or.2017.5535.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.